The association of MROH5 with neutropenia appeared to be due to independent sets of SNPs in patients treated with XELOX (lead SNP rs76380775 OR = 4.8, 95% CI = 2.4-9.5, P = 1.4 × 10−6) as compared to those receiving XELOX + cetuximab (lead SNP rs12056882 OR = 4.4, 95% CI = 1.4-14, P = 1.0 × 10−2; Supplementary Figure 6). This evidence concerns the gene MROH5 and neutropenia.